Visiting Professor Lecture Series: Multimodal Treatment of ADHD – James Swanson, PhD
Long-term patterns of medication use in the MTA follow-up, and relevance to recommendation #12 of the AACAP Practice Parameter for ADHD
- Define “consistent treatment” as the duration of uninterrupted treatment with stimulant medication in the long-term follow-up of the MTA.
- Describe treatment selection biases based on association of baseline and outcome variables with initiation and duration of uninterrupted treatment.
- Characterize the longitudinal trajectories of medication use as annual observations of frequency (% Days Treated per year) and intensity (Absolute and Relative Daily Dose for days treated).
Friday, September 20, 2019
9:00 am – 10:30 am ESTAdd to Cal
Child Mind Institute
101 East 56th Street
New York, NY 10022
About the Professor
James Swanson, PhD
- Director, Child Development Center, Pediatrics, UC Irvine School of Medicine
- Professor, Pediatrics, UC Irvine School of Medicine
- Professor, Epidemiology, UC Irvine School of Medicine
Dr. Swanson’s research focuses on attention deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults. As one of the Principal Investigators of the NIH-funded 6-site Multimodal Treatment Study of ADHD (the MTA), initiated in 1993 as 14-month randomized clinical trial of pharmacological and psychosocial interventions, he conducted collaborative research to evaluate long-term effects of stimulant medication delivered by-protocol. For the continuation of the MTA as a long-term observational follow-up until 2013, he described naturalistic patterns of treatment as-usual from childhood, during adolescence, and into adulthood to evaluate effects of extended treatment with stimulant medication on the trajectories of symptom severity, growth, and emerging comorbid problems (e.g., substance use) during childhood, through adolescence, and into adulthood.
Also, in research programs at the UC Irvine Child Development Center that he founded in 1983, Dr. Swanson established a school-based intensive intervention program for children with attention and conduct problems, developed a laboratory school protocol for measuring short-term pharmacodynamic effects of stimulant medication by monitoring behavioral and cognitive change across the day in controlled settings, and conducted studies of children, adolescence, and adults with ADHD in collaboration with experts in molecular genetics, neuropsychology, brain imaging, and auxology.
The Child Mind Institute Visiting Professor Lecture Series invites leaders in the field of child and adolescent mental health to talk about the latest research and treatment protocols. These lectures are open to the public and are available live via webinar, but are not available for viewing after the event. Continuing medical education credits (CME) are offered for medical professionals through our partnership with Northwell Health.
Northwell Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Northwell Health designates this live activity for a maximum of 1.5 AMA PRA Category 1 credits ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Northwell Health adheres to the ACCME’s Standards for Commercial Support. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with commercial interests. All relevant conflicts of interest will be resolved prior to the commencement of the activity.
Planner and Speaker’s Disclosures:
Harold Koplewicz, MD, Ron Steingard, MD, and John Q. Young, MD, have nothing to disclose. Dr. James Swanson, PhD discloses he previously received an honorarium from NLS Pharmaceutics, for speaking at an advisory board meeting.
Recognition of Program Support:
An announcement of program support will be made to all attendees at the beginning of each Regularly Scheduled Session.